Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Two affiliated Chinese drug manufacturers targeted by forthcoming US national security legislation are working on sales of some of their operations, according to people familiar with the matter.
WuXi AppTec and WuXi Biologics are among five China-based companies targeted by the Biosecure Act, which would ban drugmakers with US government contracts from using the Chinese…
Read the full article here